

UK MND Clinical Studies Group

The need for efficacy evidence of edaravone

The UK MND Clinical Studies Group, having reviewed the available evidence on the efficacy of edaravone, has agreed the following Position Statement:

The CSG believes a properly designed, randomised placebo-controlled phase 3 trial of oral edaravone is required to determine the treatment's efficacy.

Aleksandar Radunovic, Consultant Neurologist
Amina Chaouch, Consultant Neurologist
Ammar Al Chalabi, Consultant Neurologist
Andrea Malaspina, Consultant Neurologist
Ashwin Pinto, Consultant Neurologist
Brian Dickie, Research Director, MND Association
Carolyn Young, Consultant Neurologist
Chris McDermott, Consultant Neurologist
Christina Faull, Palliative Care Consultant
George Gorrie, Consultant Neurologist
Hisham Hamdalla, Consultant Neurologist
Ian Morrison, Consultant Neurologist
Janine Vince, Lay Advisor (family carer of patient with MND)
John Ealing, Consultant Neurologist
Karen Morrison, Consultant Neurologist
Kevin Talbot, Consultant Neurologist
Lisa Milella, Lay Advisor (patient with MND)
Martin Turner, Consultant Neurologist
Mary O'Brien, Professor of Palliative and Support Care
Muhammad Rafiq, Consultant Neurologist
Nick Cole, Head of Research, MND Association
Nicola Drewry, Lay Advisory (patient with MND)
Nigel Leigh, Consultant Neurologist
Oliver Hanemann, Consultant Neurologist
Pamela Shaw, Consultant Neurologist
Rhys Roberts, Consultant Neurologist
Richard Davenport, Consultant Neurologist
Richard Orrell, Consultant Neurologist
Siddharthan Chandran, Consultant Neurologist
Stacy Young, Clinical Research Manager
Suresh Chhetri, Consultant Neurologist
Tim Williams, Consultant Neurologist